| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Sale of assets | 0 | 0 |
| Net cash provided by(used in) investing activities | 0 | 0 |
| Reverse stock split rounding adjustment | 0 | - |
| Loss on sale of assets | 0 | 0 |
| Amortization of discount on preferred stock | 0 | 0 |
| Other liabilities-Nonrelated Party | - | -212,316 |
| Inventory | 0 | 0 |
| Other liabilities-Related Party | - | 9,175 |
| Accrued liabilities - related parties | 0 | 30,000 |
| Net loss | -17,874,085 | -10,255,309 |
| Depreciation | 757 | 502 |
| Issuance of common stock for services | 10,656,692 | 5,113,591 |
| Loss on debt settlement | -125,625 | - |
| Options vested for stock-based compensation | 1,201,751 | 101,958 |
| Operating lease right of use asset | 48,282 | 31,823 |
| Amortization of license agreement | 435,625 | 695,811 |
| Amortization on intangible assets | 839,672 | 554,913 |
| Prepaid expenses | 100,000 | 0 |
| Accounts payable and accrued liabilities | 153,838 | 430,494 |
| Operating lease right of use liabilities | -52,795 | -34,845 |
| Payroll tax liabilities | 4,460 | 2,973 |
| Other liabilities | -212,316 | - |
| Net cash used in operating activities | -4,772,494 | -3,531,230 |
| Proceeds from borrowings on notes payable | 500,000 | 500,000 |
| Proceeds from borrowings on notes payable - related parties | 100,000 | 100,000 |
| Proceeds from sales of common stock | 2,410,356 | 1,085,785 |
| Proceeds from sales of series b convertible preferred stock | 100,000 | 100,000 |
| Proceeds from exercise of warrants | 927,000 | 630,000 |
| Proceeds from exercise of warrants | - | 1,150,000 |
| Collection of subscriptions receivable | 1,150,000 | - |
| Net cash provided by financing activities | 5,187,356 | 3,565,785 |
| End of period | 414,862 | 34,555 |
| Cash and cash equivalents at beginning of period | 58,653 | 58,653 |
| Effect of exchange rate changes on cash | 7,766 | 7,811 |
| Cash and cash equivalents at end of period | 481,281 | 101,019 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)